Depression
Conditions
Interventions
Active -rTMS group:stable antidepressant regimen and rTMS
Sham -rTM group:stable antidepressant regimen and pseudo rTMS
Sponsors
Beijing Anding Hospital, Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. DSM-5 diagnosis of depressive disorder, single or recurrent episodes; 2. A total score of at least 20 on the HAMD-17 and Montgomery-Asberg Depression Rating Scale; 3. Aged 18-65 years, female or male; 4. Inadequate response to at least one antidepressant trial of adequate doses and duration; 5. The MSM (Maudsley Staging Method) score >= 7; 6. Stable antidepressant regimen for at least 4 weeks before treatment; 7. Educated for at least 5 years; 8. Understand the trial and sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. A lifetime psychiatric history of psychotic disorders, bipolar I or II disorders, obsessive-compulsive disorder, secondary depression, etc; 2. Implanted electronic devices (e.g. pacemakers, cochlear implants) or other metallic implants; or contraindications to MRI or contraindications to rTMS treatment; 3. History of seizure disorder (at least 2 unprovoked seizures separated by more than 24 hours, or diagnosis of epilepsy syndrome, or seizures within the past 12 months); 4. Prior treatment with electroconvulsive therapy (ECT), rTMS, or light therapy within 3 months; 5. Systemic brain disease (e.g. ischemic stroke, brain tumor) or traumatic brain injury); 6. Severe heart, liver, kidney disease, diabetes, and other serious physical diseases, etc. 7. Women who were pregnant, breastfeeding, and intend or may become pregnant during the trial; 8. Drug and alcohol abuse within the past year; 9. First-degree relative with bipolar disorder; 10. Serious suicidal ideation/behavior (e.g. item 10 of MADRS >= 5 points); 11. Difficult to communicate or understand or follow instructions, and be unable to cooperate with the treatment and assessment; 12. Currently participant in clinical trials of other drugs or physical therapy (e.g deep brain stimulation, ECT, rTMS); 13. Investigators think that was inappropriate to participate.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Hamilton Depression Scale (HAMD);Hamilton Anxiety Rating Scale (HAMA);Clinical Global Impression Scale-Severity (CGI-S);Global Assessment of Functioning (GAF);Frequency, Intensity, Burden of Side Effects Rating (FIBSER); | — |
Primary
| Measure | Time frame |
|---|---|
| Montgomery-Asberg Depression Rating Scale (MADRS); | — |
Countries
China
Contacts
Public ContactWang Gang
Beijing Anding Hospital Capital Medical University
Outcome results
None listed